Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia.

Mansour MR, He S, Li Z, Lobbardi R, Abraham BJ, Hug C, Rahman S, Leon TE, Kuang YY, Zimmerman MW, Blonquist T, Gjini E, Gutierrez A, Tang Q, Garcia-Perez L, Pike-Overzet K, Anders L, Berezovskaya A, Zhou Y, Zon LI, Neuberg D, Fielding AK, Staal FJT, Langenau DM, Sanda T, Young RA, Look AT.

J Exp Med. 2018 Jul 2;215(7):1929-1945. doi: 10.1084/jem.20170484. Epub 2018 Jun 25.

2.

Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia.

Akahane K, Li Z, Etchin J, Berezovskaya A, Gjini E, Masse CE, Miao W, Rocnik J, Kapeller R, Greenwood JR, Tiv H, Sanda T, Weinstock DM, Look AT.

Br J Haematol. 2017 Apr;177(2):271-282. doi: 10.1111/bjh.14563. Epub 2017 Mar 14.

3.

APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.

Li Z, Abraham BJ, Berezovskaya A, Farah N, Liu Y, Leon T, Fielding A, Tan SH, Sanda T, Weintraub AS, Li B, Shen S, Zhang J, Mansour MR, Young RA, Look AT.

Leukemia. 2017 Oct;31(10):2057-2064. doi: 10.1038/leu.2017.75. Epub 2017 Mar 6.

4.

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells.

Etchin J, Berezovskaya A, Conway AS, Galinsky IA, Stone RM, Baloglu E, Senapedis W, Landesman Y, Kauffman M, Shacham S, Wang JC, Look AT.

Leukemia. 2017 Jan;31(1):143-150. doi: 10.1038/leu.2016.145. Epub 2016 May 23.

5.

Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice.

Etchin J, Montero J, Berezovskaya A, Le BT, Kentsis A, Christie AL, Conway AS, Chen WC, Reed C, Mansour MR, Ng CE, Adamia S, Rodig SJ, Galinsky IA, Stone RM, Klebanov B, Landesman Y, Kauffman M, Shacham S, Kung AL, Wang JC, Letai A, Look AT.

Leukemia. 2016 Jan;30(1):190-9. doi: 10.1038/leu.2015.194. Epub 2015 Jul 23.

6.

Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.

Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, Etchin J, Lawton L, Sallan SE, Silverman LB, Loh ML, Hunger SP, Sanda T, Young RA, Look AT.

Science. 2014 Dec 12;346(6215):1373-7. doi: 10.1126/science.1259037. Epub 2014 Nov 13.

7.

Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia.

Mansour MR, Reed C, Eisenberg AR, Tseng JC, Twizere JC, Daakour S, Yoda A, Rodig SJ, Tal N, Shochat C, Berezovskaya A, DeAngelo DJ, Sallan SE, Weinstock DM, Izraeli S, Kung AL, Kentsis A, Look AT.

Br J Haematol. 2015 Jan;168(2):230-8. doi: 10.1111/bjh.13115. Epub 2014 Sep 26.

8.

Ex vivo expansion of human CD8+ T cells using autologous CD4+ T cell help.

Butler MO, Imataki O, Yamashita Y, Tanaka M, Ansén S, Berezovskaya A, Metzler G, Milstein MI, Mooney MM, Murray AP, Mano H, Nadler LM, Hirano N.

PLoS One. 2012;7(1):e30229. doi: 10.1371/journal.pone.0030229. Epub 2012 Jan 12.

9.

IL-21 can supplement suboptimal Lck-independent MAPK activation in a STAT-3-dependent manner in human CD8(+) T cells.

Imataki O, Ansén S, Tanaka M, Butler MO, Berezovskaya A, Milstein MI, Kuzushima K, Nadler LM, Hirano N.

J Immunol. 2012 Feb 15;188(4):1609-19. doi: 10.4049/jimmunol.1003446. Epub 2012 Jan 11.

10.

Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell.

Tanaka M, Butler MO, Ansén S, Imataki O, Berezovskaya A, Nadler LM, Hirano N.

Clin Cancer Res. 2011 Aug 15;17(16):5392-401. doi: 10.1158/1078-0432.CCR-10-3083. Epub 2011 Jun 24.

11.

Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells.

Butler MO, Friedlander P, Milstein MI, Mooney MM, Metzler G, Murray AP, Tanaka M, Berezovskaya A, Imataki O, Drury L, Brennan L, Flavin M, Neuberg D, Stevenson K, Lawrence D, Hodi FS, Velazquez EF, Jaklitsch MT, Russell SE, Mihm M, Nadler LM, Hirano N.

Sci Transl Med. 2011 Apr 27;3(80):80ra34. doi: 10.1126/scitranslmed.3002207.

12.

A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles.

Butler MO, Ansén S, Tanaka M, Imataki O, Berezovskaya A, Mooney MM, Metzler G, Milstein MI, Nadler LM, Hirano N.

Int Immunol. 2010 Nov;22(11):863-73. doi: 10.1093/intimm/dxq440. Epub 2010 Nov 8.

13.

Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21.

Ansén S, Butler MO, Berezovskaya A, Murray AP, Stevenson K, Nadler LM, Hirano N.

Clin Cancer Res. 2008 Oct 1;14(19):6125-36. doi: 10.1158/1078-0432.CCR-08-1146.

14.

Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.

Butler MO, Lee JS, Ansén S, Neuberg D, Hodi FS, Murray AP, Drury L, Berezovskaya A, Mulligan RC, Nadler LM, Hirano N.

Clin Cancer Res. 2007 Mar 15;13(6):1857-67.

15.

Twisted gastrulation (Tsg) is regulated by Tob and enhances TGF-beta signaling in activated T lymphocytes.

Tzachanis D, Li L, Lafuente EM, Berezovskaya A, Freeman GJ, Boussiotis VA.

Blood. 2007 Apr 1;109(7):2944-52.

16.

A pathway regulated by cell cycle inhibitor p27Kip1 and checkpoint inhibitor Smad3 is involved in the induction of T cell tolerance.

Li L, Iwamoto Y, Berezovskaya A, Boussiotis VA.

Nat Immunol. 2006 Nov;7(11):1157-65. Epub 2006 Oct 1.

PMID:
17013388
17.

Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia.

Hirano N, Butler MO, Xia Z, Berezovskaya A, Murray AP, Ansén S, Kojima S, Nadler LM.

Blood. 2006 Oct 15;108(8):2662-8. Epub 2006 Jun 15.

18.

Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses.

Hirano N, Butler MO, Xia Z, Berezovskaya A, Murray AP, Ansén S, Nadler LM.

Clin Cancer Res. 2006 May 15;12(10):2967-75.

19.

Rap1-GTP is a negative regulator of Th cell function and promotes the generation of CD4+CD103+ regulatory T cells in vivo.

Li L, Greenwald RJ, Lafuente EM, Tzachanis D, Berezovskaya A, Freeman GJ, Sharpe AH, Boussiotis VA.

J Immunol. 2005 Sep 1;175(5):3133-9.

20.

RIAM, an Ena/VASP and Profilin ligand, interacts with Rap1-GTP and mediates Rap1-induced adhesion.

Lafuente EM, van Puijenbroek AA, Krause M, Carman CV, Freeman GJ, Berezovskaya A, Constantine E, Springer TA, Gertler FB, Boussiotis VA.

Dev Cell. 2004 Oct;7(4):585-95.

21.

Differential localization and function of ADP-ribosylation factor-6 in anergic human T cells: a potential marker for their identification.

Tzachanis D, Appleman LJ, Van Puijenbroek AA, Berezovskaya A, Nadler LM, Boussiotis VA.

J Immunol. 2003 Aug 15;171(4):1691-6.

22.
23.

Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells.

Tzachanis D, Freeman GJ, Hirano N, van Puijenbroek AA, Delfs MW, Berezovskaya A, Nadler LM, Boussiotis VA.

Nat Immunol. 2001 Dec;2(12):1174-82.

PMID:
11694881
24.
25.

IL-10-producing T cells suppress immune responses in anergic tuberculosis patients.

Boussiotis VA, Tsai EY, Yunis EJ, Thim S, Delgado JC, Dascher CC, Berezovskaya A, Rousset D, Reynes JM, Goldfeld AE.

J Clin Invest. 2000 May;105(9):1317-25.

26.

p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes.

Boussiotis VA, Freeman GJ, Taylor PA, Berezovskaya A, Grass I, Blazar BR, Nadler LM.

Nat Med. 2000 Mar;6(3):290-7.

PMID:
10700231
27.

CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression.

Appleman LJ, Berezovskaya A, Grass I, Boussiotis VA.

J Immunol. 2000 Jan 1;164(1):144-51.

28.

CD4+ T cells mature in the absence of MHC class I and class II expression in Ly-6A.2 transgenic mice.

Henderson SC, Berezovskaya A, English A, Palliser D, Rock KL, Bamezai A.

J Immunol. 1998 Jul 1;161(1):175-82.

29.

Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1.

Boussiotis VA, Freeman GJ, Berezovskaya A, Barber DL, Nadler LM.

Science. 1997 Oct 3;278(5335):124-8.

30.

Regulated expression of Ly-6A.2 is important for T cell development.

Bamezai A, Palliser D, Berezovskaya A, McGrew J, Higgins K, Lacy E, Rock KL.

J Immunol. 1995 May 1;154(9):4233-9.

PMID:
7722283

Supplemental Content

Loading ...
Support Center